Medivir to present data on additive efficacy of fostrox in triple combination with anti-PD1 and kinase inhibitor in nonclinical tumor models at AACR
Medivir AB (Nasdaq Stockholm: MVIR) announced that it will present data on its leading program, fostroxacitabine bralpamide (fostrox), at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023, in Orlando, USA. The presentation, led by CSO Fredrik Öberg, will cover the anti-tumor effects of fostrox combined with an anti-PD1 antibody and a kinase inhibitor. The study suggests that this combination may enhance tumor antigen presentation and immune response, addressing the significant unmet medical need in treating hepatocellular carcinoma (HCC), which accounts for high cancer mortality rates.
- None.
- None.
The abstract, titled "A triple combination of fostrox (MIV-818) with immune checkpoint and kinase inhibition shows increased anti-tumor efficacy in vivo" will be presented at the conference by Fredrik Öberg, CSO at
- "Inhibition of angiogenesis has the potential to increase the effect of fostrox and the induction of DNA damage and tumor cell death. This can lead to increased tumor antigen presentation and a strengthened immune response, which creates opportunities to combine with both checkpoint inhibitors and tyrosine kinase inhibitors. In line with this, our preclinical results show that fostrox has the potential to amplify anti-tumor activity together with a combination of anti-PD-1 antibodies and kinase inhibitors", says Fredrik Öberg.
- "Although existing combination therapies for HCC can prolong patients' lives, far from all patients respond to treatment. In order for more patients to have a satisfactory treatment effect, new combination options with several different, additive mechanisms of action will be crucial. Fostrox, with its unique, liver-directed approach, opens up for completely new combinations with three different approaches to effectively treat HCC.", says
The abstract and the poster will be available on
For additional information, please contact
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com
About fostrox
Fostroxis a pro-drug designed to selectively treat liver cancers and to minimize side effects. It has the potential to become the first liver-targeted and orally administered drug for patients with HCC and other forms of liver cancer. Fostrox has completed a phase 1b monotherapy study, and a combination study in HCC currently ongoing.
About primary liver cancer
Primary liver cancer is the third leading cause of cancer-related deaths worldwide and hepatocellular carcinoma (HCC) is the most common cancer that arises in the liver. Although existing therapies for advanced HCC can extend the lives of patients, treatment benefits are insufficient and death rates remain high. There are 42,000 patients diagnosed with primary liver cancer per year in the US and current five-year survival is 11 percent. HCC is a heterogeneous disease with diverse etiologies, and lacks defining mutations observed in many other cancers. This has contributed to the lack of success of molecularly targeted agents in HCC. The limited overall benefit, taken together with the poor overall prognosis for patients with intermediate and advanced HCC, results in a large unmet medical need.
About
The following files are available for download:
Press release (PDF) |
View original content:SOURCE
FAQ
What is the focus of Medivir AB's research?
When will Medivir present new research on fostrox?
What is fostrox and its significance in cancer treatment?
What are the expected benefits of combining fostrox with other therapies?
What is the current prognosis for patients with hepatocellular carcinoma?
Which companies are associated with Medivir's drug development?
